journal
MENU ▼
Read by QxMD icon Read
search

Lancet. Gastroenterology & Hepatology

journal
https://read.qxmd.com/read/31005605/the-international-liver-congress-2019
#1
Rob Brierley
No abstract text is available yet for this article.
April 17, 2019: Lancet. Gastroenterology & Hepatology
https://read.qxmd.com/read/31003962/dilation-after-small-biliary-sphincterotomy
#2
Paraskevas Gkolfakis, Marianna Arvanitakis
No abstract text is available yet for this article.
April 16, 2019: Lancet. Gastroenterology & Hepatology
https://read.qxmd.com/read/31003961/optimal-dilation-time-for-combined-small-endoscopic-sphincterotomy-and-balloon-dilation-for-common-bile-duct-stones-a-multicentre-single-blinded-randomised-controlled-trial
#3
Wenbo Meng, Joseph W Leung, Kai Zhang, Wence Zhou, Zhenyu Wang, Leida Zhang, Hao Sun, Ping Xue, Wei Liu, Qi Wang, Jijun Zhang, Xuefeng Wang, Meng Wang, Yingmei Shao, Kailin Cai, Senlin Hou, Qiyong Li, Lei Zhang, Kexiang Zhu, Ping Yue, Haiping Wang, Ming Zhang, Xiangyu Sun, Zhiqing Yang, Jie Tao, Zilong Wen, Qunwei Wang, Bendong Chen, Quan Shao, Mingning Zhao, Ruoyan Zhang, Tiemin Jiang, Ke Liu, Lichao Zhang, Kangjie Chen, Xiaoliang Zhu, Hui Zhang, Long Miao, Zhengfeng Wang, Jiajia Li, Xiaowen Yan, Fangzhao Wang, Lingen Zhang, Azumi Suzuki, Kiyohito Tanaka, Ula Nur, Elisabete Weiderpass, Xun Li
BACKGROUND: Endoscopic sphincterotomy is the established treatment for common bile duct stones. Balloon dilation offers an alternative. Prolonged dilation (300 s) with a 10 mm diameter balloon decreases the occurrence of pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP). We aimed to determine the optimal duration of dilation for combined endoscopic sphincterotomy and balloon dilation for the removal of common bile duct stones. METHODS: We did a multicentre, single-blinded, randomised controlled trial at 15 tertiary surgical centres in China...
April 16, 2019: Lancet. Gastroenterology & Hepatology
https://read.qxmd.com/read/30982722/hepatitis-b-virus-infection-in-children-and-adolescents
#4
REVIEW
Giuseppe Indolfi, Philippa Easterbrook, Geoffrey Dusheiko, George Siberry, Mei-Hwei Chang, Claire Thorne, Marc Bulterys, Po-Lin Chan, Manal H El-Sayed, Carlo Giaquinto, Maureen M Jonas, Tammy Meyers, Nick Walsh, Stefan Wirth, Martina Penazzato
Hepatitis B virus (HBV) infection is a major cause of acute and chronic liver disease and associated morbidity and mortality worldwide. Vertical (mother-to-child) and horizontal early childhood transmission are the main routes of HBV transmission and are responsible for most chronic infections, including among adults who bear the greatest burden of morbidity and mortality. Universal hepatitis B immunisation at birth and in infancy is the key strategy for global elimination of HBV infection, and has been highly effective in reducing new vertical infections...
April 10, 2019: Lancet. Gastroenterology & Hepatology
https://read.qxmd.com/read/30982721/hepatitis-c-virus-infection-in-children-and-adolescents
#5
REVIEW
Giuseppe Indolfi, Philippa Easterbrook, Geoffrey Dusheiko, Manal H El-Sayed, Maureen M Jonas, Claire Thorne, Marc Bulterys, George Siberry, Nick Walsh, Mei-Hwei Chang, Tammy Meyers, Carlo Giaquinto, Stefan Wirth, Po-Lin Chan, Martina Penazzato
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease and associated morbidity and mortality worldwide. Short-course, oral, curative, direct-acting antiviral regimens have transformed treatment for HCV infection. Since the 2016 launch of the first global strategy towards elimination of viral hepatitis as a public health threat by 2030, the predominant focus of the global response has been on the treatment of adults, who bear the greatest burden of morbidity and mortality of HCV-related chronic liver disease...
April 10, 2019: Lancet. Gastroenterology & Hepatology
https://read.qxmd.com/read/30981687/how-can-we-achieve-who-s-elimination-target-for-hepatitis-c-incidence
#6
Anne Lindebo Holm Øvrehus, Håvard Midgard
No abstract text is available yet for this article.
April 10, 2019: Lancet. Gastroenterology & Hepatology
https://read.qxmd.com/read/30981686/a-global-scientific-strategy-to-cure-hepatitis-b
#7
Peter A Revill, Francis V Chisari, Joan M Block, Maura Dandri, Adam J Gehring, Haitao Guo, Jianming Hu, Anna Kramvis, Pietro Lampertico, Harry L A Janssen, Massimo Levrero, Wenhui Li, T Jake Liang, Seng-Gee Lim, Fengmin Lu, M Capucine Penicaud, John E Tavis, Robert Thimme, Fabien Zoulim
Chronic hepatitis B virus (HBV) infection is a global public health challenge on the same scale as tuberculosis, HIV, and malaria. The International Coalition to Eliminate HBV (ICE-HBV) is a coalition of experts dedicated to accelerating the discovery of a cure for chronic hepatitis B. Following extensive consultation with more than 50 scientists from across the globe, as well as key stakeholders including people affected by HBV, we have identified gaps in our current knowledge and new strategies and tools that are required to achieve HBV cure...
April 10, 2019: Lancet. Gastroenterology & Hepatology
https://read.qxmd.com/read/30981685/the-contribution-of-injection-drug-use-to-hepatitis-c-virus-transmission-globally-regionally-and-at-country-level-a-modelling-study
#8
Adam Trickey, Hannah Fraser, Aaron G Lim, Amy Peacock, Samantha Colledge, Josephine G Walker, Janni Leung, Jason Grebely, Sarah Larney, Natasha K Martin, Matthew Hickman, Louisa Degenhardt, Margaret T May, Peter Vickerman
BACKGROUND: WHO aims to eliminate the hepatitis C virus (HCV) as a public health threat by 2030. Injection drug use is an important risk factor for HCV transmission, but its contribution to country-level and global epidemics is unknown. We estimated the contribution of injection drug use to risk for HCV epidemics globally, regionally, and at country level. METHODS: We developed a dynamic deterministic HCV transmission model to simulate country-level HCV epidemics among people who inject drugs and the general population...
April 10, 2019: Lancet. Gastroenterology & Hepatology
https://read.qxmd.com/read/30975477/optimisation-of-the-use-of-apri-and-fib-4-to-rule-out-cirrhosis-in-patients-with-chronic-hepatitis-b-results-from-the-sonic-b-study
#9
Milan J Sonneveld, Willem P Brouwer, Henry L-Y Chan, Teerha Piratvisuth, Ji-Dong Jia, Stefan Zeuzem, Yun-Fan Liaw, Bettina E Hansen, Hannah Choi, Cynthia Wat, Vedran Pavlovic, Anuj Gaggar, Qing Xie, Maria Buti, Robert J de Knegt, Harry L A Janssen
BACKGROUND: Ruling out the presence of cirrhosis is important for the management of chronic hepatitis B. We aimed to study and optimise the performance of two non-invasive indices for ruling out cirrhosis: the aspartate aminotransferase-platelet ratio index (APRI) and fibrosis score based on four factors (FIB-4). METHODS: We applied established cutoffs to rule in (APRI >2·00; FIB-4 >3·25) or rule out (APRI <1·00; FIB-4 <1·45) cirrhosis to data from eight global randomised trials that required baseline biopsy, and identified new cutoffs aiming for a sensitivity for detection of cirrhosis greater than 90% and a negative predictive value (NPV) of greater than 95% in the same dataset...
April 8, 2019: Lancet. Gastroenterology & Hepatology
https://read.qxmd.com/read/30975476/a-simple-non-invasive-test-for-ruling-out-cirrhosis-in-chronic-hepatitis-b
#10
Tai-Chung Tseng, Yi-Fen Shih, Chun-Jen Liu
No abstract text is available yet for this article.
April 8, 2019: Lancet. Gastroenterology & Hepatology
https://read.qxmd.com/read/30954567/doxorubicin-loaded-nanoparticles-for-patients-with-advanced-hepatocellular-carcinoma-after-sorafenib-treatment-failure-relive-a-phase-3-randomised-controlled-trial
#11
Philippe Merle, Jean-Frederic Blanc, Jean-Marc Phelip, Gilles Pelletier, Jean-Pierre Bronowicki, Yann Touchefeu, Georges Pageaux, René Gerolami, François Habersetzer, Eric Nguyen-Khac, Andrea Casadei-Gardini, Ivan Borbath, Albert Tran, Henning Wege, Amr Shafik Saad, Massimo Colombo, Armand Abergel, Carine Richou, Imam Waked, Nelson S Yee, Audrey Molé, Pierre Attali, Julie Le Boulicaut, Bérangère Vasseur
BACKGROUND: Cytotoxic chemotherapy is generally ineffective in patients with hepatocellular carcinoma. We assessed the intravenous perfusion of doxorubicin-loaded nanoparticles in patients with hepatocellular carcinoma in whom previous sorafenib therapy had failed. METHODS: We did a multicentre, open-label, randomised, controlled phase 3 trial at 70 sites in 11 countries. Patients with hepatocellular carcinoma with one or more previous systemic therapies, including sorafenib, were randomly assigned to receive 30 mg/m2 doxorubicin-loaded nanoparticles (30 mg/m2 group), 20 mg/m2 doxorubicin-loaded nanoparticles (20 mg/m2 group), or standard care using a computer-generated randomisation list prepared by the funder and stratified by geographic region...
April 3, 2019: Lancet. Gastroenterology & Hepatology
https://read.qxmd.com/read/30954566/systemic-doxorubicin-and-hepatocellular-carcinoma-the-end-of-an-era-never-risen-up
#12
Marco Sanduzzi-Zamparelli, Alejandro Forner
No abstract text is available yet for this article.
April 3, 2019: Lancet. Gastroenterology & Hepatology
https://read.qxmd.com/read/30922873/long-term-efficacy-and-safety-of-obeticholic-acid-for-patients-with-primary-biliary-cholangitis-3-year-results-of-an-international-open-label-extension-study
#13
Michael Trauner, Frederik Nevens, Mitchell L Shiffman, Joost P H Drenth, Christopher L Bowlus, Victor Vargas, Pietro Andreone, Gideon M Hirschfield, Richard Pencek, Elizabeth Smoot Malecha, Leigh MacConell, David Shapiro
BACKGROUND: The aim of this study was to evaluate the long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis using 3-year interim data from the 5-year open-label extension of the pivotal phase 3 POISE trial. METHODS: In the double-blind phase of POISE, 217 patients with primary biliary cholangitis with inadequate response to or intolerance to ursodeoxycholic acid were randomised to receive placebo, obeticholic acid 5 to 10 mg, or obeticholic acid 10 mg once daily for 12 months...
March 25, 2019: Lancet. Gastroenterology & Hepatology
https://read.qxmd.com/read/30922872/long-term-outcomes-with-obeticholic-acid-in-primary-biliary-cholangitis-reassuring-but-still-an-itch-we-need-to-scratch
#14
John E Eaton, Gregory J Gores
No abstract text is available yet for this article.
March 25, 2019: Lancet. Gastroenterology & Hepatology
https://read.qxmd.com/read/30902671/the-increasing-clinical-burden-of-nafld-in-asia
#15
Marianne Anastasia De Roza, George Boon-Bee Goh
No abstract text is available yet for this article.
March 19, 2019: Lancet. Gastroenterology & Hepatology
https://read.qxmd.com/read/30902670/prevalence-incidence-and-outcome-of-non-alcoholic-fatty-liver-disease-in-asia-1999-2019-a-systematic-review-and-meta-analysis
#16
Jie Li, Biyao Zou, Yee Hui Yeo, Yuemin Feng, Xiaoyu Xie, Dong Hyun Lee, Hideki Fujii, Yuankai Wu, Leslie Y Kam, Fanpu Ji, Xiaohe Li, Nicholas Chien, Mike Wei, Eiichi Ogawa, Changqing Zhao, Xia Wu, Christopher D Stave, Linda Henry, Scott Barnett, Hirokazu Takahashi, Norihiro Furusyo, Yuichiro Eguchi, Yao-Chun Hsu, Teng-Yu Lee, Wanhua Ren, Chengyong Qin, Dae Won Jun, Hidenori Toyoda, Vincent Wai-Sun Wong, Ramsey Cheung, Qiang Zhu, Mindie H Nguyen
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease worldwide. Asia is a large, heterogeneous area with substantial variation in socioeconomic status and prevalence of obesity. We estimated the prevalence, incidence, and outcomes of NAFLD in the Asian population to assist stakeholders in understanding NAFLD disease burden. METHODS: We searched PubMed, EMBASE, and the Cochrane Library from database inception to Jan 17, 2019, for studies reporting NAFLD prevalence, incidence, or outcome in Asia...
March 19, 2019: Lancet. Gastroenterology & Hepatology
https://read.qxmd.com/read/30885505/feasibility-and-economic-assessment-of-chromocolonoscopy-for-detection-of-proximal-serrated-neoplasia-within-a-population-based-colorectal-cancer-screening-programme-conscop-an-open-label-randomised-controlled-non-inferiority-trial
#17
Chris Hurt, Rajeswari Ramaraj, Angela Farr, Meleri Morgan, Namor Williams, Ceri J Philips, Geraint T Williams, Georgina Gardner, Catherine Porter, Julian Sampson, Sharon Hillier, Hayley Heard, Sunil Dolwani
BACKGROUND: Most post-colonoscopy interval colorectal cancers are proximal; serrated polyps are often precursors to these cancers and are considered difficult to detect. We assessed the safety, feasibility, and economic effect of chromocolonoscopy on detection of proximal serrated neoplasia. METHODS: We did an open-label, multicentre, randomised, controlled non-inferiority trial including patients from Bowel Screening Wales centres. Participants who tested positive for faecal occult blood and who were eligible for and considered fit to have colonoscopy (patients with known cases of polyposis syndromes, Lynch syndrome, and chronic inflammatory disease were excluded) were randomly assigned (1:1; with the use of minimisation, stratified by centre with an 80:20 random element) to either standard white light colonoscopy (standard group) or chromocolonoscopy (indigo carmine dye [0·2%]; chromocolonoscopy group) using a secure, internet-based, computerised, randomisation system that used centralised, dynamic allocation...
March 15, 2019: Lancet. Gastroenterology & Hepatology
https://read.qxmd.com/read/30885504/chromoendoscopy-for-detection-of-proximal-serrated-lesions-in-routine-screening-colonoscopy
#18
Anna Buchner
No abstract text is available yet for this article.
March 15, 2019: Lancet. Gastroenterology & Hepatology
https://read.qxmd.com/read/30852136/reduced-dose-combination-chemotherapy-s-1-plus-oxaliplatin-versus-full-dose-monotherapy-s-1-in-older-vulnerable-patients-with-metastatic-colorectal-cancer-nordic9-a-randomised-open-label-phase-2-trial
#19
Stine Braendegaard Winther, Gabor Liposits, Halla Skuladottir, Eva Hofsli, Carl-Henrik Shah, Laurids Østergaard Poulsen, Jesper Ryg, Pia Osterlund, Åke Berglund, Camilla Qvortrup, Bengt Glimelius, Halfdan Sorbye, Per Pfeiffer
BACKGROUND: Older or vulnerable patients with metastatic colorectal cancer are seldom included in randomised trials. The multicentre NORDIC9 trial evaluated reduced-dose combination chemotherapy compared with full-dose monotherapy in older, vulnerable patients. METHODS: This randomised, open-label phase 2 trial was done in 23 Nordic oncology clinics and included patients aged 70 years or older with previously untreated metastatic colorectal cancer who were not candidates for full-dose combination chemotherapy...
March 6, 2019: Lancet. Gastroenterology & Hepatology
https://read.qxmd.com/read/30852135/how-best-to-treat-older-patients-with-metastatic-colorectal-cancer
#20
Julien Taieb
No abstract text is available yet for this article.
March 6, 2019: Lancet. Gastroenterology & Hepatology
journal
journal
53645
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"